Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair: An Analysis of 1,092 Patients.

IF 1.3 4区医学 Q3 ORTHOPEDICS

Orthopedics Pub Date : 2026-09-01 DOI:10.3928/01477447-20260811-01

Elliot Forst, Lindsey Tully, Thomas E Moran, Alyssa D Althoff

{"title":"Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair: An Analysis of 1,092 Patients.","authors":"Elliot Forst, Lindsey Tully, Thomas E Moran, Alyssa D Althoff","doi":"10.3928/01477447-20260811-01","DOIUrl":null,"url":null,"abstract":"Background: Diabetes and obesity are recognized as risk factors for postoperative complications including increased surgical site infection (SSI) and reoperation in patients undergoing knee extensor mechanism repair. However, limited literature evaluates how preoperative glucagon-like peptide-1 (GLP-1) receptor agonist therapy may influence these outcomes. This study evaluated GLP-1 receptor agonist use as an independent risk factor for postoperative outcomes following knee extensor mechanism repair.Materials and methods: Patients who underwent quadriceps or patellar tendon repair from 2012 to 2025 were identified in the TriNetX database and stratified by GLP-1 agonist use within 1 year of surgery. One-to-one propensity score matching yielded 2 well-balanced cohorts (n = 546). Postoperative complications were assessed at 90 days, 1 year, and 2 years, and Kaplan-Meier survival analysis was performed.Results: No significant 90-day postoperative differences were observed. At 1 year, patients using GLP-1 agonists demonstrated significantly lower rates of SSI (2.38% vs 5.31%; odds ratio [OR] = 0.435; P = .0118) and wound complications (2.02% vs 5.31%; OR = 0.367; P = .0037). Differences persisted at 2 years, with lower rates of SSI (2.75% vs 6.04%; OR = 0.439; P = .0079), wound complications (2.38% vs 6.04%; OR = 0.379; P = .0026), and acute kidney injury (9.71% vs 13.55%; OR = 0.686; P = .0474). No significant differences in revision surgery were found. Kaplan-Meier analysis demonstrated significant separation for SSI and wound complications beginning at 1 year.Conclusion: Preoperative GLP-1 receptor agonist therapy was associated with reduced postoperative SSI and wound complications following knee extensor mechanism repair. These findings suggest potential for perioperative risk modulation as GLP-1 use becomes increasingly prevalent in patients undergoing knee extensor mechanism repair.","PeriodicalId":19631,"journal":{"name":"Orthopedics","volume":" ","pages":"e383-e390"},"PeriodicalIF":1.3000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Orthopedics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/01477447-20260811-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ORTHOPEDICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes and obesity are recognized as risk factors for postoperative complications including increased surgical site infection (SSI) and reoperation in patients undergoing knee extensor mechanism repair. However, limited literature evaluates how preoperative glucagon-like peptide-1 (GLP-1) receptor agonist therapy may influence these outcomes. This study evaluated GLP-1 receptor agonist use as an independent risk factor for postoperative outcomes following knee extensor mechanism repair.

Materials and methods: Patients who underwent quadriceps or patellar tendon repair from 2012 to 2025 were identified in the TriNetX database and stratified by GLP-1 agonist use within 1 year of surgery. One-to-one propensity score matching yielded 2 well-balanced cohorts (n = 546). Postoperative complications were assessed at 90 days, 1 year, and 2 years, and Kaplan-Meier survival analysis was performed.

Results: No significant 90-day postoperative differences were observed. At 1 year, patients using GLP-1 agonists demonstrated significantly lower rates of SSI (2.38% vs 5.31%; odds ratio [OR] = 0.435; P = .0118) and wound complications (2.02% vs 5.31%; OR = 0.367; P = .0037). Differences persisted at 2 years, with lower rates of SSI (2.75% vs 6.04%; OR = 0.439; P = .0079), wound complications (2.38% vs 6.04%; OR = 0.379; P = .0026), and acute kidney injury (9.71% vs 13.55%; OR = 0.686; P = .0474). No significant differences in revision surgery were found. Kaplan-Meier analysis demonstrated significant separation for SSI and wound complications beginning at 1 year.

Conclusion: Preoperative GLP-1 receptor agonist therapy was associated with reduced postoperative SSI and wound complications following knee extensor mechanism repair. These findings suggest potential for perioperative risk modulation as GLP-1 use becomes increasingly prevalent in patients undergoing knee extensor mechanism repair.

查看原文本刊更多论文

GLP-1激动剂与膝关节伸肌机制修复术后并发症的关系：1092例患者的分析

背景：糖尿病和肥胖被认为是膝关节伸肌机制修复患者术后并发症的危险因素，包括手术部位感染（SSI）和再手术的增加。然而，有限的文献评估术前胰高血糖素样肽-1 （GLP-1）受体激动剂治疗如何影响这些结果。本研究评估GLP-1受体激动剂作为膝关节伸肌机制修复术后预后的独立危险因素。材料和方法：从TriNetX数据库中确定2012年至2025年接受股四头肌或髌骨肌腱修复的患者，并根据手术1年内GLP-1激动剂的使用进行分层。一对一倾向评分匹配产生2个平衡良好的队列（n = 546）。术后90天、1年和2年评估并发症，并进行Kaplan-Meier生存分析。结果：术后90天无明显差异。1年后，使用GLP-1激动剂的患者SSI发生率（2.38% vs 5.31%；优势比[OR] = 0.435; P = 0.0118）和伤口并发症发生率（2.02% vs 5.31%; OR = 0.367; P = 0.0037）显著降低。差异持续2年，SSI发生率（2.75% vs 6.04%; OR = 0.439; P = 0.0079）、伤口并发症发生率（2.38% vs 6.04%; OR = 0.379; P = 0.0026）和急性肾损伤发生率（9.71% vs 13.55%; OR = 0.686; P = 0.0474）较低。在翻修手术方面没有发现显著差异。Kaplan-Meier分析显示，SSI和伤口并发症在1年后开始显著分离。结论：术前GLP-1受体激动剂治疗可减少术后SSI和膝关节伸肌机制修复后的伤口并发症。这些发现表明，在接受膝关节伸肌机制修复的患者中，随着GLP-1的使用越来越普遍，围手术期风险调节的可能性越来越大。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Orthopedics 医学-整形外科

CiteScore

2.20

自引率

0.00%

发文量

160

审稿时长

3 months

期刊介绍： For over 40 years, Orthopedics, a bimonthly peer-reviewed journal, has been the preferred choice of orthopedic surgeons for clinically relevant information on all aspects of adult and pediatric orthopedic surgery and treatment. Edited by Robert D''Ambrosia, MD, Chairman of the Department of Orthopedics at the University of Colorado, Denver, and former President of the American Academy of Orthopaedic Surgeons, as well as an Editorial Board of over 100 international orthopedists, Orthopedics is the source to turn to for guidance in your practice. The journal offers access to current articles, as well as several years of archived content. Highlights also include Blue Ribbon articles published full text in print and online, as well as Tips & Techniques posted with every issue.